Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF

Human Gene Therapy

Volumn 7, Issue 15, 1996, Pages 1853-1860

  Qin, Hongxing ^a   Chatterjee, Sunil K ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CANCER VACCINE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CELL SPECIFICITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENE THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR CELL; TUMOR VOLUME; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALIA; ESCHERICHIA COLI; MURINAE; VACCINIA; VACCINIA VIRUS;

EID: 0029856952     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.15-1853     Document Type: Article

References (28)

1. BASH, J.A. (1993). Recombinant vaccinia interleukin-2-infected tumor cells vaccines in immunotherapy of murine colon adenocarcinoma. J. Immunother. 14, 269-272.
2. BUBENIK, J., and INDROVA, M. (1987). Cancer immunotherapy using local interleukin 2 administration. Immunol. Lett. 16, 305-310.
3. CONRY, R.M., SALEH, M.N., SCHLOM, J., and LOBUGLIO, A.F. (1995). Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus vaccine in man. Proc. Am. Assoc. Cancer Res. 36, 492.
4. DRANOFF, G., JAFFE, E.M., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D.M., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90, 3538-3543.
5. DUBINETT, S.M., PATRONE, L., TOBIAS, J., COCHRAN, A.J., and WEN, D.R. (1993). Intratumoral interleukin-2 immunotherapy: Activation of tumor-infiltrating and splenic lymphocytes in vivo. Cancer Immunol. Immunother. 36, 156-162.
6. ELKINS, K., ENNIST, D.L., WINEGAR, R.K., and WEIR, J.P. (1994). In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice. Hum. Gene Ther. 5, 809-820.
7. FAKHRAI, H., SHAWLER, D.L., GJERSET, R., NAVIAUX, R.K. KOZIOL, J., ROYSTON, I., and SOBOL, R.E. (1995). Cytokine gene therapy with interleukin-2-transduced fibroblasts: Effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther. 6, 591-601.
8. FEARON, E.R., PARDOLL, D.M., ITAYA, T., GOLUMBEK, P., LEVITSKY, H.I., SIMONS, J.W., KARASUYAMA, H., VOGELSTEIN, B., and FROST, P. (1990). Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
9. FIDLER, I.J. (1975). Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35, 218-224.
10. FLEXNER, C., HUGIN, A., and MOSS, B. (1987). Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330, 259-262.
11. FOX, B.A., SPIESS, P.J., KASID, A., PURI, R., MULE, J.J., WEBER, J.S., and ROSENBERG, S.A. (1990). In vitro and in vivo anti-tumor properties of a T-cell clone generated from murine tumor infiltrating lymphocytes. J. Biol. Response Mod. 9, 499-511.
12. GANSBACHER, B., BANNERJI, R., DANIELS, B., ZIER, K., CRONIN, K., and GILBOA, E. (1990a). Retroviral vector-mediated γ-interferon gene transfer into tumor cells generate potent and long lasting anti-tumor immunity. Cancer Res. 50, 7820-7825.
13. GANSBACHER, B., ZIER, K., DANIELS, K.C., BANNERJI, R., and GILBOA, E. (1990b). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
14. GILLIES, S.D., REILLY, E.B., LO, K.M., and REISFELD, R.A. (1992). Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA 89, 1428-1432.
15. GOUGH, N.M., METCALF, D., GOUGH, J., GRAIL, D., and DUNN, R.A. (1985). Structure and expression of the mRNA for murine GM-CSF. EMBO J. 4, 645-653.
16. MACKETT, M, SMITH, G.L., and MOSS, B. (1985). The construction and characterization of vaccinia virus recombinants expressing foreign genes. In DNA Cloning, vol. II. D.M. Glover, ed. (IRL Press, Oxford, UK) pp. 191-212.
17. MEKO, J.B., YIM, J.H., TSUNG, K., and NORTON, J.A. (1995). High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res. 55, 4765-4770.
18. PARDOLL, D.M. (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 399-415.
19. QIN, H-X., and CHATTERJEE, S.K. (1996a). Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine. Gene Ther. 3, 59-66.
20. QIN, H-X., and CHATTERJEE, S.K. (1996b). Recombinant vaccinia virus expressing interleukin-2 for cancer gene therapy. Cancer Gene Ther. 3, 163-167.
21. ROSENBERG, S.A. (1992). The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10, 180-199.
22. SAITO, S., BANNERJI, R., GANSBACHER, B., ROSENTHAL, F.M., ROMANENKO, P. HESTON, W.D.W., FAIR, W.R., and GILBOA, E. (1994). Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 54, 3516-3520.
23. SCHMIDT, W.S., SCHWEIGHOFFER, T., HERBST, E., MAASS, G., BERGER, M., SCHILCHER, F., SCHAFFNER, G., and BIRNSTIEL, M.I. (1995). Cancer vaccines: The interleukin 2 dosage effect. Proc. Natl. Acad. Sci. USA 92, 4711-4714.
24. SUTTER, G., and MOSS, B. (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89, 10847-10851.
25. TEPPER, R.I., PATTENGALE, P.K., and LEDER, P. (1989). Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57, 503-512.
26. TSANG, K.Y., KANTOR, J., ABRAMS, S., PANICALI, D., HAMILTON, J., and SCHLOM, J. (1995). A recombinant CEA-vaccinia induces a CEA-specific cytotoxic T-cell response in carcinoma patients. Proc. Am. Assoc. Cancer Res. 36, 249.
27. WANG, M., BRONTE, V., CHEN, P.W., GRITZ, L., PANICALI, D., ROSENBERG, S.A., and RESTIFO, N.P. (1995). Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154, 4685-4692.
28. WATANABE, Y., KURIBAYASHI, K., MIYATAKE, S., NISHIHARA, K., NAKAYAMA, E.I., TANIYAMA, T., and SAKATA, T.A. (1989). Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA 86, 9456-9460.